Your shopping cart is currently empty

5Z-7-Oxozeaenol (FR148083) is a potent, irreversible and selective inhibitor of transforming growth factor (TGF)-β-activated kinase 1 with IC50 of 8.1 nM for TAK1 and low activity against MEK1 with IC50 of 411 nM, it is also an inhibitor of VEGF-R2 with IC50 of 52 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $363 | 35 days | 35 days | |
| 5 mg | Inquiry | 35 days | 35 days |
| Description | 5Z-7-Oxozeaenol (FR148083) is a potent, irreversible and selective inhibitor of transforming growth factor (TGF)-β-activated kinase 1 with IC50 of 8.1 nM for TAK1 and low activity against MEK1 with IC50 of 411 nM, it is also an inhibitor of VEGF-R2 with IC50 of 52 nM. |
| Targets&IC50 | TAK1:8.1 nM, MEK1:411 nM, VEGFR3:110 nM, FLT3:170 nM, VEGFR2:52 nM, PDGFRβ:340 nM, Src:6600 nM, B-Raf (VE):6300 nM |
| In vitro | 5Z-7-Oxozeaenol is a natural anti-protozoan compound from the fungal origin with inhibitory activity against VEGF-R3, FLT3, PDGFR-β, B-RAF VE, and SRC with IC50s of 110, 170, 340, 6300, and 6600 nM, respectively[1]. 5Z-7-Oxozaeenol inhibited PMA-induced AP-1 activity to almost basal levels in KT cells but had no effect on IL-1-induced NF-kB activity in KK cells[2]. 5Z-7-Oxozaeenol inhibits the JNK/p38 pathway, but it is not a direct inhibitor and is signal-specific. 5Z-7-Oxozaeenol prevents inflammation by inhibiting the catalytic activity of the TAK1 MAPK kinase[3]. |
| Synonyms | LL-Z 1640-2, L783279, FR148083 |
| Molecular Weight | 362.37 |
| Formula | C19H22O7 |
| Cas No. | 253863-19-3 |
| Smiles | COc1cc(O)c2c(c1)\C=C\C[C@H](O)[C@H](O)C(=O)\C=C/C[C@H](C)OC2=O |
| Relative Density. | 1.270 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (110.38 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (5.52 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.